Lista de obras - Carmen Escuriola Ettingshausen

A review of immune tolerance induction with Haemate P in haemophilia A.

artículo científico

Abstracts from the 10th C1-inhibitor deficiency workshop.

artículo científico publicado en 2017

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

artículo científico publicado en 2016

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease

artículo científico publicado en 2002

Common themes and challenges in hemophilia care: a multinational perspective

artículo científico publicado en 2018

Delayed diagnosis of hereditary angioedema: Thirty-nine years of inadequate treatment

artículo científico publicado en 2016

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

artículo científico publicado en 2009

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys

artículo científico publicado en 2007

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

artículo científico publicado en 1999

Epidemiology of inhibitors and current treatment strategies

artículo científico publicado en 2003

Epidemiology of inhibitors in haemophilia A.

artículo científico publicado en 1996

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

artículo científico publicado en 2013

Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.

artículo científico publicado en 1995

Factor VIII products and inhibitor development in severe hemophilia A.

artículo científico publicado en 2013

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

artículo científico publicado en 2015

Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?

artículo científico publicado en 2003

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab

artículo científico publicado en 2008

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.

artículo científico publicado en 2011

Immune tolerance induction: What have we learned over time?

artículo científico publicado en 2018

Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study

artículo científico publicado en 2014

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates

artículo científico publicado en 2005

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products

artículo científico publicado en 2002

Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports.

artículo científico publicado en 2009

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

artículo científico publicado en 2006

Inhibitors in patients with haemophilia A.

artículo científico

Inhibitors: A Need for Eradication?

scientific article published on 15 February 2019

Long-term aspects of hemophilia B treatment: part I-role for prophylaxis

artículo científico publicado en 2004

Management of bleeding disorders in children

scientific article published on 01 May 2012

Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy

artículo científico publicado en 2002

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.

artículo científico publicado en 2006

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

scientific article published on 13 November 2019

Prevention of joint damage in hemophilic children with early prophylaxis

artículo científico publicado en 1999

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

artículo científico publicado en 2018

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

artículo científico publicado en 2015

Protein-C concentrate for meningococcal purpura fulminans

artículo científico publicado en 1998

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

artículo científico publicado en 1998

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

artículo científico publicado en 2007

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development

artículo científico publicado en 2006

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

artículo científico publicado en 2017

Role of von Willebrand factor in immune tolerance induction

artículo científico publicado en 2005

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.

artículo científico publicado en 2015

Successful management of hereditary angioedema during pregnancy in a patient with heterozygous MTHFR mutation

artículo científico publicado en 2017

Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors

artículo científico publicado en 2001

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.

artículo científico publicado en 2017

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

artículo científico publicado en 2009

The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study)

scientific article published on 29 March 2019

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

artículo científico publicado en 2013

The importance of inhibitor eradication in clinically complicated hemophilia A patients

article

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis

artículo científico publicado en 2015

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

artículo científico publicado en 1998

[Prevention of joint damage in hemophilic children with early prophylaxis]

artículo científico publicado en 1999

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

scientific article published on 19 April 2020

Lista de obras de Carmen Escuriola Ettingshausen

A review of immune tolerance induction with Haemate P in haemophilia A.

Abstracts from the 10th C1-inhibitor deficiency workshop.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease

Common themes and challenges in hemophilia care: a multinational perspective

Delayed diagnosis of hereditary angioedema: Thirty-nine years of inadequate treatment

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

Epidemiology of inhibitors and current treatment strategies

Epidemiology of inhibitors in haemophilia A.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.

Factor VIII products and inhibitor development in severe hemophilia A.

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.

Immune tolerance induction: What have we learned over time?

Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products

Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

Inhibitors in patients with haemophilia A.

Inhibitors: A Need for Eradication?

Long-term aspects of hemophilia B treatment: part I-role for prophylaxis

Management of bleeding disorders in children

Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

Prevention of joint damage in hemophilic children with early prophylaxis

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

Protein-C concentrate for meningococcal purpura fulminans

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Role of von Willebrand factor in immune tolerance induction

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.

Successful management of hereditary angioedema during pregnancy in a patient with heterozygous MTHFR mutation

Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study)

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

The importance of inhibitor eradication in clinically complicated hemophilia A patients

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

[Prevention of joint damage in hemophilic children with early prophylaxis]

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment